{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:31Z","timestamp":1787024611470,"version":"build-2736575974"},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"11","funder":[{"name":"Shandong Province 2022 College Students Innovation Training Program project","award":["S202310426045"],"award-info":[{"award-number":["S202310426045"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is a high-indence malignance of the digestive\nsystem with a high mortality rate in the world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The results are desired to provide an important theoretical basis for discovering new therapeutic\ntargets for CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The expression of human endogenous retrovirus-H-long terminal repeat association\nprotein 2 (HHLA2) in human CRC was detected to explore its correlationship with clinicopathological\nfeatures and prognosis of patients and its potential in treating CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Western blot was employed to detect HHLA2 expression in fresh tissues obtained from\n6 CRC patients' excisions, including cancer, paracancer, and normal issues. Immunohistochemical\nstaining was employed to determine HHLA2 expression in paraffin-embedded specimens of 139\npatients with colorectal cancer, and its relationship with the clinicopathological profiles and survival\nwas analyzed. Small interfering RNA (siRNA) targeting HHLA2 was used to transfect CRC\ncells to silent HHLA2. MTT, plate colony formation, cell scratch, and Transwell assay were conducted\nto observe the proliferation, migration, and invasion of CRC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>HHLA2 protein was expressed in human colorectal cancer tissues, paracancer tissues and\nnormal tissues, which was significantly upregulated in cancer tissues (P &lt; 0.01). HHLA2 expression\nlevel in CRC tissues showed a close correlationship with the invasion depth of the tumor (P =\n0.000), metastasis of regional lymph nodes (P = 0.018), clinical stage (P = 0.010), and patient survival\n(P = 0.011). Correlation with gender (P = 0.873), age (P = 0.864), location of the tumor (P =\n0.768), degree of tumor differentiation (P = 0.569) and distant metastasis (P = 0.494) exhibited no\nsignificance. The survival time of CRC patients with high and low HHLA2 expression groups was\n43.231 months and 55.649 months, respectively, with a statistical difference between the two\ngroups (P = 0.001). Silencing HHLA2 inhibited proliferation, migration and invasion of CRC\ncells significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HHLA2 is overexpressed in CRC tissues which is associated with poor prognosis of\npatients. HHLA2 might be recognized as a new candidate for adjuvant diagnosis and prognosis of\nCRC, as well as a promised new target for immunotherapy of CRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115680096290709240102064645","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:04:24Z","timestamp":1706763864000},"page":"1177-1186","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Significance of HHLA2 as a Novel Therapeutic Target for\nColorectal Cancer"],"prefix":"10.2174","volume":"24","author":[{"given":"Hongbo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, the People's Hospital of Jimo, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"An","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, the People's Hospital of Jimo, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, the People's Hospital of Jimo, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, the People's Hospital of Jimo, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, the People's Hospital of Jimo, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1158\/1535-7163.MCT-17-0193","volume":"17","author":"Malvicini M.","year":"2018","unstructured":"Malvicini M.; Gutierrez-Moraga A.; Rodriguez M.M.; Gomez-Bustillo S.; Salazar L.; Sunkel C.; Nozal L.; Salgado A.; Hidalgo M.; Lopez-Casas P.P.; Novella J.L.; Vaquero J.J.; Alvarez-Builla J.; Mora A.; Gidekel M.; Mazzolini G.; A tricin derivative from deschampsia antarctica Desv. Inhibits colorectal carcinoma growth and liver metastasis through the induction of a specific immune response. Mol Cancer Ther  2018,17(5),966-976","journal-title":"Mol Cancer Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1136\/gut.2006.098053","volume":"55","author":"Garden O. J.","year":"2006","unstructured":"Garden O. J.; Rees M.; Poston G. J.; Mirza D.; Saunders M.; Ledermann J.; Primrose J. N.; Parks R. W.; Guidelines for resection of colorectal cancer liver metastases. Gut  2006,55(S3),iii1-iii8","journal-title":"Gut"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=4","first-page":"2193","volume":"18","author":"Besharati F.","year":"2017","unstructured":"Besharati F.; Karimi-Shahanjarini A.; Hazavehei S.M.M.; Bashirian S.; Bagheri F.; Faradmal J.; Development of a colorectal cancer screening intervention for iranian adults: Appling intervention mapping. Asian Pac J Cancer Prev  2017,18(8),2193-2199","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000454685","volume":"33","author":"Wild A.T.","year":"2017","unstructured":"Wild A.T.; Yamada Y.; Treatment options in oligometastatic disease: Stereotactic body radiation therapy - focus on colorectal cancer. Visc Med  2017,33(1),54-61","journal-title":"Visc Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e000157","DOI":"10.1136\/jitc-2019-000157","volume":"8","author":"Zhou Q.H.","year":"2020","unstructured":"Zhou Q.H.; Li K.W.; Chen X.; He H.X.; Peng S.M.; Peng S.R.; Wang Q.; Li Z.A.; Tao Y.R.; Cai W.L.; Liu R.Y.; Huang H.; HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer  2020,8(1),e000157","journal-title":"J Immunother Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41423-020-0361-7","volume":"18","author":"Rieder S.A.","year":"2021","unstructured":"Rieder S.A.; Wang J.; White N.; Qadri A.; Menard C.; Stephens G.; Karnell J.L.; Rudd C.E.; Kolbeck R.; B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling. Cell Mol Immunol  2021,18(6),1503-1511","journal-title":"Cell Mol Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000495887","volume":"141","author":"Lin G.","year":"2019","unstructured":"Lin G.; Ye H.; Wang J.; Chen S.; Chen X.; Zhang C.; Immune checkpoint human endogenous retrovirus-H long terminal repeat-associating protein 2 is upregulated and independently predicts unfavorable prognosis in bladder urothelial carcinoma. Nephron J  2019,141(4),256-264","journal-title":"Nephron J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2147\/OTT.S160493","volume":"11","author":"Zhu Z.","year":"2018","unstructured":"Zhu Z.; Dong W.; Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. OncoTargets Ther  2018,11,1563-1570","journal-title":"OncoTargets Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12033-011-9422-6","volume":"51","author":"Mo R.H.","year":"2012","unstructured":"Mo R.H.; Zaro J.L.; Ou J.H.J.; Shen W.C.; Effects of Lipofectamine 2000\/siRNA complexes on autophagy in hepatoma cells. Mol Biotechnol  2012,51(1),1-8","journal-title":"Mol Biotechnol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db12-1139","volume":"62","author":"Escande C.","year":"2013","unstructured":"Escande C.; Nin V.; Price N.L.; Capellini V.; Gomes A.P.; Barbosa M.T.; O\u2019Neil L.; White T.A.; Sinclair D.A.; Chini E.N.; Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes  2013,62(4),1084-1093","journal-title":"Diabetes"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3109\/1061186X.2011.622404","volume":"19","author":"Taratula O.","year":"2011","unstructured":"Taratula O.; Garbuzenko O.B.; Chen A.M.; Minko T.; Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target  2011,19(10),900-914","journal-title":"J Drug Target"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e14406","DOI":"10.1111\/jfbc.14406","volume":"46","author":"Zhang M.","year":"2022","unstructured":"Zhang M.; Qiu B.; Sun M.; Wang Y.; Wei M.; Gong Y.; Yan M.; Preparation of Black pepper (Piper nigrum L.) essential oil nanoparticles and its antitumor activity on triple negative breast cancer in vitro. J Food Biochem  2022,46(12),e14406","journal-title":"J Food Biochem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"772101","DOI":"10.3389\/fphar.2021.772101","volume":"12","author":"Lucaf\u00f2 M.","year":"2021","unstructured":"Lucaf\u00f2 M.; Curci D.; Franzin M.; Decorti G.; Stocco G.; Inflammatory bowel disease and risk of colorectal cancer: An overview from pathophysiology to pharmacological prevention. Front Pharmacol  2021,12,772101","journal-title":"Front Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1067\/j.cpsurg.2018.02.003","volume":"55","author":"Xue L.","year":"2018","unstructured":"Xue L.; Williamson A.; Gaines S.; Andolfi C.; Paul-Olson T.; Neerukonda A.; Steinhagen E.; Smith R.; Cannon L.M.; Polite B.; Umanskiy K.; Hyman N.; An update on colorectal cancer. Curr Probl Surg  2018,55(3),76-116","journal-title":"Curr Probl Surg"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.prp.2015.05.010","volume":"211","author":"Cao H.","year":"2015","unstructured":"Cao H.; Xu E.; Liu H.; Wan L.; Lai M.; Epithelial\u2013mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract  2015,211(8),557-569","journal-title":"Pathol Res Pract"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","volume":"35","author":"Abbott M.","year":"2019","unstructured":"Abbott M.; Ustoyev Y.; Cancer and the immune system: The history and background of immunotherapy. Semin Oncol Nurs  2019,35(5),150923","journal-title":"Semin Oncol Nurs"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","volume":"122","author":"Marcus A.","year":"2014","unstructured":"Marcus A.; Gowen B.G.; Thompson T.W.; Iannello A.; Ardolino M.; Deng W.; Wang L.; Shifrin N.; Raulet D.H.; Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol  2014,122,91-128","journal-title":"Adv Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","volume":"10","author":"Im A.","year":"2017","unstructured":"Im A.; Pavletic S.Z.; Immunotherapy in hematologic malignancies: Past, present, and future. J Hematol Oncol  2017,10(1),94","journal-title":"J Hematol Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3747\/co.25.3840","volume":"25","author":"Nixon N.A.","year":"2018","unstructured":"Nixon N.A.; Blais N.; Ernst S.; Kollmannsberger C.; Bebb G.; Butler M.; Smylie M.; Verma S.; Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol  2018,25(5),373-384","journal-title":"Curr Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"9879","DOI":"10.1073\/pnas.1303524110","volume":"110","author":"Zhao R.","year":"2013","unstructured":"Zhao R.; Chinai J.M.; Buhl S.; Scandiuzzi L.; Ray A.; Jeon H.; Ohaegbulam K.C.; Ghosh K.; Zhao A.; Scharff M.D.; Zang X.; HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci  2013,110(24),9879-9884","journal-title":"Proc Natl Acad Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cei.13413","volume":"200","author":"Zhong C.","year":"2020","unstructured":"Zhong C.; Lang Q.; Yu J.; Wu S.; Xu F.; Tian Y.; Phenotypical and potential functional characteristics of different immune cells expressing CD28H\/B7-H5 and their relationship with cancer prognosis. Clin Exp Immunol  2020,200(1),12-21","journal-title":"Clin Exp Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-14-1495","volume":"21","author":"Janakiram M.","year":"2015","unstructured":"Janakiram M.; Chinai J.M.; Fineberg S.; Fiser A.; Montagna C.; Medavarapu R.; Castano E.; Jeon H.; Ohaegbulam K.C.; Zhao R.; Zhao A.; Almo S.C.; Sparano J.A.; Zang X.; Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res  2015,21(10),2359-2366","journal-title":"Clin Cancer Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e1026534","DOI":"10.1080\/2162402X.2015.1026534","volume":"4","author":"Janakiram M.","year":"2015","unstructured":"Janakiram M.; Chinai J.M.; Zhao A.; Sparano J.A.; Zang X.; HHLA2 and TMIGD2: New immunotherapeutic targets of the B7 and CD28 families. OncoImmunology  2015,4(8),e1026534","journal-title":"OncoImmunology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.31557\/APJCP.2021.22.6.1883","volume":"22","author":"Farrag M.","year":"2021","unstructured":"Farrag M.; Ibrahim E.; El-Hadidy T.; Akl M.; Elsergany A.; Abdelwahab H.; Human endogenous retrovirus-H long terminal repeat- associating protein 2 (HHLA2) is a novel immune checkpoint protein in lung cancer which predicts survival. Asian Pac J Cancer Prev  2021,22(6),1883-1889","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680096290709240102064645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/226530\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680096290709240102064645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T02:27:15Z","timestamp":1727922435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/226530\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115680096290709240102064645","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}